dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Danielewicz, I. |
dc.contributor.author | Saunders, M. P. |
dc.contributor.author | Pfeiffer, P. |
dc.contributor.author | Argilés Martinez, Guillem |
dc.contributor.author | Borg, Christophe |
dc.date.accessioned | 2022-09-05T11:46:14Z |
dc.date.available | 2022-09-05T11:46:14Z |
dc.date.issued | 2022-06-01 |
dc.identifier.citation | Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer. 2022 Jun 1;126:1548–1554. |
dc.identifier.issn | 1532-1827 |
dc.identifier.uri | https://hdl.handle.net/11351/8027 |
dc.description | Colorectal cancer |
dc.description.abstract | Background
Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall survival (OS) results.
Methods
TASCO1 was an open-label, non-comparative phase II trial. Patients (n = 153) were randomised 1:1 to TT-B (trifluridine/tipiracil 35 mg/m2 orally twice daily on days 1–5 and 8–12, and bevacizumab intravenously 5 mg/kg on days 1 and 15 of each 28-day cycle) or capecitabine plus bevacizumab (C-B; capecitabine, 1250 mg/m2 orally twice daily on days 1–14 and bevacizumab 7.5 mg/kg intravenously on day 1 of each 21-day cycle). Final OS was analysed when all patients had either died or withdrawn from the study. Adjusted multivariate regression was used to investigate the effects of pre-specified variables on OS.
Results
At 1 September 2020, median OS was 22.3 months (95% CI: 18.0–23.7) with TT-B and 17.7 months (95% CI: 12.6–19.8) with C-B (adjusted HR 0.78; 95% CI: 0.55–1.10). No variables negatively affected OS with TT-B. Safety results were consistent with prior findings.
Conclusions
TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | British Journal of Cancer;126 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Survival Analysis |
dc.title | First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41416-022-01737-2 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | análisis de supervivencia |
dc.relation.publishversion | https://doi.org/10.1038/s41416-022-01737-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Van Cutsem E] University Hospitals Leuven and KU Leuven, Leuven, Belgium. [Danielewicz I] Wojewodzkie Hospitals in Gdyni/Gdansk Medical University, Gdynia, Poland. [Saunders MP] Christie Hospital NHS Foundation Trust, Manchester, UK. [Pfeiffer P] Odense University Hospital, Odense, Denmark. [Argilés G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borg C] University Hospital Besançon, Besançon, France |
dc.identifier.pmid | 35440667 |
dc.identifier.wos | 000784850700003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |